Wall Street brokerages expect Catalent Inc (NYSE:CTLT) to post $0.29 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Catalent’s earnings. The lowest EPS estimate is $0.24 and the highest is $0.35. Catalent posted earnings per share of $0.21 in the same quarter last year, which would indicate a positive year-over-year growth rate of 38.1%. The company is scheduled to announce its next earnings results on Tuesday, November 6th.
On average, analysts expect that Catalent will report full-year earnings of $1.88 per share for the current financial year, with EPS estimates ranging from $1.85 to $1.92. For the next fiscal year, analysts anticipate that the company will post earnings of $2.09 per share, with EPS estimates ranging from $1.95 to $2.21. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Catalent.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 6th. The company reported $0.28 EPS for the quarter, hitting analysts’ consensus estimates of $0.28. The business had revenue of $551.80 million during the quarter, compared to analysts’ expectations of $582.44 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The company’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.21 earnings per share.
A number of research firms have recently commented on CTLT. Zacks Investment Research raised shares of Catalent from a “sell” rating to a “hold” rating in a research note on Monday, October 1st. UBS Group began coverage on shares of Catalent in a research note on Tuesday, October 9th. They set a “neutral” rating and a $48.00 target price for the company. JPMorgan Chase & Co. boosted their target price on shares of Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 29th. Finally, ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $49.33.
In other Catalent news, Director Donald E. Morel, Jr. acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The stock was bought at an average price of $43.00 per share, with a total value of $430,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Lance Miyamoto sold 6,525 shares of the company’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total transaction of $277,312.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 184,335 shares of company stock valued at $8,161,727. 1.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in Catalent during the 2nd quarter valued at about $145,000. Moneta Group Investment Advisors LLC grew its stake in shares of Catalent by 105.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after buying an additional 1,800 shares during the period. CIBC Asset Management Inc purchased a new stake in shares of Catalent in the 3rd quarter valued at approximately $217,000. Chicago Equity Partners LLC purchased a new stake in shares of Catalent in the 3rd quarter valued at approximately $237,000. Finally, Hartford Investment Management Co. purchased a new stake in shares of Catalent in the 2nd quarter valued at approximately $220,000. 92.08% of the stock is owned by institutional investors.
CTLT stock opened at $36.11 on Wednesday. The stock has a market cap of $6.11 billion, a PE ratio of 22.71, a P/E/G ratio of 2.50 and a beta of 1.45. The company has a debt-to-equity ratio of 2.44, a current ratio of 2.15 and a quick ratio of 1.79. Catalent has a 52 week low of $34.24 and a 52 week high of $47.87.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Index Funds
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.